Search results

646 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Quality standards Remove Quality standards filter

Housing: planning to improve health and wellbeing

In development [GID-NG10053] Expected publication date: TBC

Type

NICE guideline

Status

In development
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250

In development [GID-TA10213] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated multiple myeloma (ID1139)

In development [GID-TA10193] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

In development [GID-TAG511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]

In development [GID-TAG508] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

In development [GID-TA10018] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

In development [GID-TA10033] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

In development [GID-TA10099] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

In development [GID-TA10204] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Assessment, referral and management of Adrenal dysfunction

In development [GID-NG10052] Expected publication date: TBC

Type

NICE guideline

Status

In development
Intravaginal sling for stress urinary incontinence

In development [GID-IP267] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503

In development [GID-TA10401] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Asunercept for treating glioblastoma [1301]

In development [GID-TA10227] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]

In development [GID-TA10225] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Kidney transplantation (rejection) - belatacept [ID87]

In development [GID-TAG239] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]

In development [GID-TA10143] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

In development [GID-TA10261] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Binimetinib for treating melanoma [ID833]

In development [GID-TA10074] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

In development [GID-TA10081] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

In development [GID-TA10088] Expected publication date: 27 December 2017

Type

Technology appraisal guidance

Status

In development
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

In development [GID-TA10087] Expected publication date: 27 December 2017

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]

In development [GID-TA10070] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

In development [GID-TAG526] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]

In development [GID-TA10045] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Masitinib for treating amyotrophic lateral sclerosis [ID967]

In development [GID-TA10157] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]

In development [GID-TA10242] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute lymphoblastic) - erythrocyte encapsulated asparaginase [ID864]

In development [GID-TA10047] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

In development [GID-TAG278] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Electrochemotherapy for the treatment of malignant melanoma

In development [GID-IP1041] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

In development [GID-TA10179] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mastocytosis (systemic) - masitinib [ID781]

In development [GID-TA10019] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

In development [GID-TA10180] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

In development [GID-TA10109] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diagnostic services

In development [GID-CGWAVE0773] Expected publication date: TBC

Type

NICE guideline

Status

In development
Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

In development [GID-TA10228] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]

In development [GID-TA10110] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

In development [GID-TA10164] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

In development [GID-TA10065] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoporosis (postmenopausal women) - abaloparatide [ID882]

In development [GID-TA10071] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]

In development [GID-TAG479] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development